Objectives The averted infections ratio (AIR) is a novel measure for quantifying the preservation-of-effect in active-control non-inferiority clinical trials with a time-to-event outcome. In the main formulation, the AIR requires an estimate of the counterfactual placebo incidence rate. We describe two approaches for calculating confidence limits for the AIR given a point estimate of this parameter, a closed-form solution based on a Taylor series expansion (delta method) and an iterative method based on the profile-likelihood. Methods For each approach, exact coverage probabilities for the lower and upper confidence limits were computed over a grid of values of (1) the true value of the AIR (2) the expected number of counterfactual events (3) the effectiveness of the active-control treatment. Results Focussing on the lower confidence limit, which determines whether non-inferiority can be declared, the coverage achieved by the delta method is either less than or greater than the nominal coverage, depending on the true value of the AIR. In contrast, the coverage achieved by the profile-likelihood method is consistently accurate. Conclusions The profile-likelihood method is preferred because of better coverage properties, but the simpler delta method is valid when the experimental treatment is no less effective than the control treatment. A complementary Bayesian approach, which can be applied when the counterfactual incidence rate can be represented as a prior distribution, is also outlined.
Inhalt
- Research Articles
-
Open AccessConfidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rate24. November 2021
-
Erfordert eine Authentifizierung Nicht lizenziertSample size calculation for active-arm trial with counterfactual incidence based on recency assayLizenziert10. November 2021
-
4. November 2021
-
Open AccessEvaluating the power of the causal impact method in observational studies of HCV treatment as prevention11. Oktober 2021
-
Erfordert eine Authentifizierung Nicht lizenziertGLM based auto-regressive process to model Covid-19 pandemic in TurkeyLizenziert4. Juni 2021
-
Erfordert eine Authentifizierung Nicht lizenziertContact network uncertainty in individual level models of infectious disease transmissionLizenziert8. Januar 2021